Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AK112, a PD-1VEGF bispecific antibody, as a consolidation treatment for patients with limited stage small cell lung cancer who have not shown disease progression after concurrent chemoradiation therapy. This phase III, randomized, double-blind study aims to compare the effectiveness and safety of AK112 against a placebo in this specific patient group. Participants will receive either AK112 or a placebo intravenously every three weeks as consolidation therapy following their initial chemoradiation. The study includes two groups one receiving AK112 at a dose of 20 mgkg every three weeks, and the other receiving a matching placebo on the same schedule. Treatment continues under close monitoring to assess outcomes. Throughout the study, participants will undergo regular assessments including scans and evaluations to monitor progression-free survival and overall survival over approximately six years. Additional outcome measures include response rates and disease control rates assessed by both independent review and investigators, along with safety monitoring for adverse events. This long-term follow-up helps researchers understand how the treatments perform and their impact on patient health.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of pegmolesatide, a long-acting erythropoiesis-stimulating agent ESA, in patients with renal anemia who are currently treated with hypoxia-inducible factor prolyl hydroxylase inhibitors HIF-PHIs. This trial aims to explore the safety and effectiveness of switching from HIF-PHIs to pegmolesatide, addressing the current need for longer-acting and safe medications. The study is a multi-center, prospective, open-label, randomized parallel-controlled trial enrolling 96 dialysis chronic kidney disease patients with anemia. Participants are divided into two groups based on their current weekly Roxadustat dose a low-dose cohort 210 mg and a high-dose cohort >210 mg and 360 mg. Within each cohort, patients are randomly assigned to receive pegmolesatide at different initial doses 2 mg, 4 mg, or 6 mg administered subcutaneously once every 4 weeks. The dose may be adjusted according to the drugs instructions. The treatment period lasts 12 weeks, followed by a 16-week follow-up period. During the study, researchers will monitor hemoglobin levels and other blood parameters at various intervals to assess the effects of pegmolesatide. Patients will undergo assessments including hemoglobin tests, red blood cell counts, and safety monitoring for adverse events. The primary measurement is the change in mean hemoglobin levels from baseline to 12 and 16 weeks. The total participation time for each patient is 28 weeks, including treatment and follow-up.
Actively Recruiting
Researchers are studying the safety and effectiveness of early use of tirofiban in patients who have acute ischemic stroke and are treated with tenecteplase. This study is exploring whether adding tirofiban soon after tenecteplase can reduce the risk of blood clot re-blockage in the brain, which happens in some patients after initial treatment. The study is a phase 3 trial aiming to improve stroke outcomes by preventing this reocclusion. Participants first receive tenecteplase intravenously for stroke treatment. Those who meet the study criteria are then randomly assigned to receive either tirofiban or a placebo. Tirofiban or placebo is given intravenously starting as soon as possible after randomization, initially as a higher dose for 30 minutes, followed by a continuous lower dose infusion for nearly 48 hours. After 24 hours, patients receive aspirin andor clopidogrel or their placebos, then after 44 hours, antiplatelet therapy with aspirin andor clopidogrel continues until the 90-day follow-up. During the study, participants undergo assessments including neurological exams and monitoring for bleeding or other adverse events. The main outcome measured is excellent functional recovery 90 days after randomization. Other outcomes include disability levels, neurological improvement, quality of life, bleeding events, and mortality. Safety and serious adverse events are tracked through the 90-day period to evaluate treatment effects and risks.
Actively Recruiting
Randomized, Double-Blind Study of Yufeng Ningxin Tablets Versus Placebo for Adults With Hypertension
Researchers are evaluating the effects of Yufeng Ningxin, a traditional Chinese medicine, on patients with hypertension. Although previous animal studies and small clinical trials have suggested that Yufeng Ningxin may lower blood pressure, this phase 4 double-blind, randomized controlled trial aims to rigorously assess its efficacy and safety in a larger patient group. The trial is sponsored by Beijing Anzhen Hospital and focuses on adults aged 18 to 65 with newly diagnosed or treated hypertension. Participants are randomly assigned to one of two groups one group receives Yufeng Ningxin tablets, and the other receives a matching placebo. Both treatments are taken as five tablets per dose, three times daily for eight weeks. The study uses a quadruple masking design to ensure unbiased results. The primary treatment period lasts eight weeks, during which participants take the study medication as directed. During the trial, participants will undergo regular blood pressure measurements and assessments of other health markers related to hypertension, including ambulatory blood pressure monitoring and blood tests for cholesterol and glucose levels. Researchers will also analyze changes in gut microbiota and headache impact scores. Safety is monitored through tracking adverse events, hospitalizations, and emergency visits throughout the eight weeks. Participants will be closely followed to measure the change in systolic blood pressure from the start to the end of treatment.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two different treatment regimens to eradicate Helicobacter pylori infection. This trial compares a dual therapy using linralase glutarate capsules combined with amoxicillin against a quadruple therapy that includes bismuth. The main goal is to see if the dual therapy is not less effective than the quadruple therapy, while also monitoring patient adherence and side effects. This is a phase 4, randomized, open-label study aimed at first-line treatment of this infection. Participants receive either the dual-drug regimen of linralase glutarate capsules 50 mg twice daily plus amoxicillin 1 g three times daily or the quadruple therapy consisting of esomeprazole 20 mg twice daily, clarithromycin 0.5 g twice daily, amoxicillin 1 g twice daily, and colloidal bismuth subcitrate 200 mg twice daily. Both treatment courses last for 14 days. The study groups are assigned randomly and monitored during and after treatment to assess outcomes. During the study, participants undergo testing to determine the Helicobacter pylori eradication rate 28 days after treatment ends. Researchers also track adverse events during the 14 days of treatment and for 28 days following treatment completion. Participants adherence to the medication regimens is evaluated throughout. The trial includes adults aged 18 to 70 years who meet specific diagnostic and health criteria. The total duration from treatment to outcome measurement spans about 6 weeks, including follow-up assessments.
Actively Recruiting
Healthy Volunteer
Researchers are studying the lot-to-lot consistency of immunogenicity and safety for a recombinant 9-valent human papillomavirus HPV vaccine made using Escherichia coli. This clinical trial focuses on females aged 18 to 30 years in China and aims to determine if immune responses are consistent across three commercial vaccine batches. The study supports international market access and meets World Health Organization Prequalification requirements. Participants receive three doses of the investigational 9-valent HPV vaccine at months 0, 1, and 6. The study includes visits at months 0, 1, 2, 6, and 7, with blood samples collected at months 0 and 7 to measure antibody levels. Participants keep diaries of adverse events for 30 days after each vaccination and report serious or special interest adverse events and pregnancies during the trial. During the study, participants undergo assessments of immune responses by measuring antibody concentrations one month after completing vaccination. Safety is monitored by documenting adverse events throughout the seven-month period. The trial evaluates geometric mean concentrations, seroconversion, and seropositivity rates of antibodies to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Overall participant involvement lasts about seven months, including vaccination and follow-up visits.
Actively Recruiting
Researchers are evaluating the complete response rate of two radiotherapy approaches combined with chemotherapy and the immune drug tislelizumab for people with locally advanced rectal cancer. This phase II study compares a modified short-course radiotherapy plus CAPOX chemotherapy and tislelizumab against the traditional long-course chemoradiotherapy plus tislelizumab. The goal is to find the best radiotherapy strategy to improve tumor shrinkage and increase the chance of complete response, aiming to offer better organ preservation options for patients. Participants are assigned to one of two groups one receives modified short-course radiotherapy targeting the tumor and lymph nodes over 5 sessions, followed by four cycles of oxaliplatin, capecitabine, and tislelizumab every three weeks the other group receives long-course radiotherapy over 25 sessions with concurrent capecitabine during radiation days and three cycles of tislelizumab every three weeks. After treatment, efficacy and surgery are evaluated. During the study, participants undergo assessments to measure complete response up to three months after neoadjuvant therapy and for up to a year after enrollment. Researchers also monitor organ preservation rates, surgical complications within 30 days, quality of life before surgery and up to 12 months after, and adverse events up to six months post-treatment. Long-term outcomes including disease-free survival, local recurrence-free survival, and overall survival are tracked for three years. The total study duration extends until 2027, with careful safety monitoring throughout.